Barinthus Biotherapeutics (BRNS) Price & Analysis

Compare

97 Followers

BRNS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.64 - $2.92

Previous CloseN/A

Volume10.26K

Average Volume (3M)2.57M

Market Cap

$48.01M

Enterprise Value-$38.17M

Total Cash (Recent Filing)$86.26M

Total Debt (Recent Filing)$11.99M

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Nov 06, 2025

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding40,718,227

10 Day Avg. Volume16,724

30 Day Avg. Volume2,574,261

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.79

Enterprise Value/Revenue-2.55

Enterprise Value/Gross Profit32.66

Enterprise Value/Ebitda0.61

Forecast

1Y Price Target

$2.00

Price Target Upside75.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe ongoing first-in-human Phase 1 AVALON trial of VTP-1000 has shown no treatment-related serious adverse events in the first two cohorts, which is promising for the drug's safety profile.

Financial StabilityThe company has a cash runway into 2027, providing a stable financial foundation to support continued research and development efforts.

Bears Say

CompetitionThe competitive landscape for celiac disease treatment includes major players like Sanofi and Teva, which are advancing their Phase 2 trials.

Financial PerformanceThe net loss of $21.2M was significantly higher than the estimated loss of $11.8M, which could raise concerns about financial performance.

Barinthus Biotherapeutics News

Barinthus Biotherapeutics reports Q2 EPS (52c) vs. (49c) last year

“In the second quarter, we remained laser-focused on advancing VTP-1000, our highly differentiated immunotherapy designed to prevent or...

22d ago

BRNS

Barinthus Biotherapeutics sees cash runway into 2027

As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8 million, compared to $100.6 million...

22d ago

BRNS

Barinthus Biotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on BRNS stock, giving a Buy rating yesterday....

21d ago

BRNS

Barinthus Biotherapeutics Reports Q2 2025 Financial Results

Barinthus Biotherapeutics Plc ( ($BRNS) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

BRNS

Barinthus Biotherapeutics Approves Key Proposals at AGM

Barinthus Biotherapeutics ( ($BRNS) ) has issued an announcement. On June 10, 2025, Barinthus Biotherapeutics held its Annual...

3M ago

BRNS

Barinthus Biotherapeutics: Strategic Advancements and Financial Strength Support Buy Rating

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Barinthus Biotherapeutics (BRNS – Research Report)....

4M ago

BRNS

Barinthus Biotherapeutics Reports Q1 2025 Financial Results

Barinthus Biotherapeutics Plc ( ($BRNS) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

BRNS

Barinthus Biotherapeutics Restructures Leadership with New CFO

Barinthus Biotherapeutics ( ($BRNS) ) has issued an update. Barinthus Biotherapeutics announced significant corporate developments, including the termination...

4M ago

BRNS

Barinthus Biotherapeutics reports Q1 EPS (49c), consensus (36c)

“2025 has started with a strategic focus on immunological and inflammatory diseases, which includes directing our resources to...

4M ago

BRNS

Barinthus Bio Reports 2024 Financial Results and Strategic Focus

Barinthus Biotherapeutics Plc ( ($BRNS) ) has released its Q4 earnings. Here is a breakdown of the information...

5M ago

BRNS

Barinthus Biotherapeutics price target lowered to $6 from $7.50 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $6 from $7.50 and keeps...

5M ago

BRNS

Barinthus Biotherapeutics reports FY24 EPS ($1.55), consensus ($1.48)

Reports FY24 revenue $15M, consensus $10M. “We’ve entered 2025 with a refreshed strategic focus on immunological and inflammatory...

5M ago

BRNS

Barinthus Biotherapeutics sees cash runway into 2027

As of December 31, 2024, cash, cash equivalents and restricted cash was $112.4 million, compared to $142.1 million...

5M ago

BRNS

BRNS Earnings this Week: How Will it Perform?

Barinthus Biotherapeutics Plc (BRNS) is scheduled to report 4th quarter earnings on 03/21/2025. Regarding Q4 estimates, Wall Street...

5M ago

BRNS

BRNS FAQ

What was Barinthus Biotherapeutics’s price range in the past 12 months?

Barinthus Biotherapeutics lowest stock price was $0.64 and its highest was $2.92 in the past 12 months.

What is Barinthus Biotherapeutics’s market cap?

Barinthus Biotherapeutics’s market cap is $48.01M.

When is Barinthus Biotherapeutics’s upcoming earnings report date?

Barinthus Biotherapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Barinthus Biotherapeutics’s earnings last quarter?

Barinthus Biotherapeutics released its earnings results on Aug 07, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.19.

Is Barinthus Biotherapeutics overvalued?

According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Barinthus Biotherapeutics pay dividends?

Barinthus Biotherapeutics does not currently pay dividends.

What is Barinthus Biotherapeutics’s EPS estimate?

Barinthus Biotherapeutics’s EPS estimate is -0.38.

How many shares outstanding does Barinthus Biotherapeutics have?

Barinthus Biotherapeutics has 40,718,227 shares outstanding.

What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?

Barinthus Biotherapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 10.687%.

Which hedge fund is a major shareholder of Barinthus Biotherapeutics?

Currently, no hedge funds are holding shares in BRNS

Barinthus Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.78%

Trailing 12-Months

Asset Growth

-30.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Barinthus Biotherapeutics

Barinthus Biotherapeutics (BRNS) is a biotechnology company specializing in the development of innovative therapeutic solutions aimed at addressing unmet medical needs. Operating primarily in the biopharmaceutical sector, Barinthus focuses on the research and development of novel biologics and advanced drug delivery systems. The company's core products include a range of targeted therapies designed to treat various chronic and life-threatening diseases.

Barinthus Biotherapeutics (BRNS) Earnings & Revenues

Historic Earnings Reports

BRNS Stock 12 Month Forecast

Average Price Target

$2.00

▲(75.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,1.523076923076923,1.646153846153846,1.7692307692307692,1.8923076923076922,2.0153846153846153,2.1384615384615384,2.2615384615384615,2.3846153846153846,2.5076923076923077,2.6307692307692307,2.753846153846154,2.876923076923077,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,1.4461538461538461,1.4923076923076923,1.5384615384615383,1.5846153846153845,1.6307692307692307,1.676923076923077,1.7230769230769232,1.7692307692307692,1.8153846153846154,1.8615384615384616,1.9076923076923076,1.953846153846154,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,1.3692307692307693,1.3384615384615384,1.3076923076923077,1.2769230769230768,1.2461538461538462,1.2153846153846153,1.1846153846153846,1.1538461538461537,1.123076923076923,1.0923076923076922,1.0615384615384615,1.0307692307692307,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.52,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >